Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT00466531

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations: Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, not recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

NCT05456698

Conditions: Acute Lymphocytic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Active, not recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Banner Gateway Medical Center Gilbert, Arizona, United States

Banner Gateway Medical Pavilion Gilbert, Arizona, United States

Banner MD Anderson Cancer Center Gilbert, Arizona, United States

Ronald Reagan UCLA Medical Center Los Angeles, California, United States

View all 209 locations

View Trial Details

Active, not recruiting

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT02420860

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03763162

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

NCT01424982

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, +28 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555

Conditions: Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: Mount Sinai Hospital New York, United States

Memorial Sloan Kettering Cancer Center New York, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

NCT02514083

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03192397

Conditions: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Anemia, +45 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions